Filana Therapeutics shareholders approved 2018 incentive plan amendment at annual meeting

• Filana Therapeutics held its annual shareholder meeting on June 11, 2026.
• Shareholders adopted an amendment to the 2018 Omnibus Incentive Plan, lifting authorized shares to 9,000,000 and extending the plan through Jan. 31, 2030.
• The amendment also bars option or SAR repricing, replacement, or cash-outs without shareholder approval, while tightening annual equity award limits.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for the year ending Dec. 31, 2026.
• Shareholders elected three directors to the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-020562), on June 15, 2026, and is solely responsible for the information contained therein.